Novel Bone Scan Features for Predicting Prognosis in Men With Bone Metastatic Prostate Cancer: A Retrospective Study

预测骨转移性前列腺癌患者预后的新型骨扫描特征:一项回顾性研究

阅读:2

Abstract

BACKGROUND: Bone metastasis frequently occurs in patients with prostate cancer, however, a consensus has not been reached regarding bone scan image analysis. We aimed to analyse various bone scan imaging features of metastatic prostate cancer and to assess their impact on prognosis. METHODS: One thousand five hundred sixty-three paired sets of bone scan images (anterior and posterior) were obtained from patients with metastatic prostate cancer at Seoul National University Hospital. U-Net architecture was used for the segmentation of metastatic bone lesions. Imaging features describing the overall metastatic burden (n = 18) and largest metastatic burden (n = 32) were extracted using computer vision techniques. Kaplan-Meier survival analysis and Cox proportional risk model were used to analyse the prognostic impact of each feature. RESULTS: The correlation coefficient between the actual number of lesions and that predicted by the deep learning model was 0.87, indicating a strong correlation. Multivariate Cox regression showed that metastasis intensity difference (hazard ratio [HR], 0.53; P = 0.002) and the largest metastasis percentage (HR, 0.62; P = 0.038) were independently associated with disease progression and were even more strongly associated with the number of metastases (current standard). The Kaplan-Meier curves revealed that a higher total metastasis ratio (P < 0.001), a lower total metastasis intensity difference (P = 0.030), a lower largest metastatic lesion percentage (P < 0.001), higher compactness (P = 0.028), and lower eccentricity (P = 0.070) were associated with shorter progression-free survival. CONCLUSION: Although the number of bone metastases is a standardised prognostic factor, additional consideration of morphological or intensity-related novel features may be useful to more accurately predict the prognosis of patients with metastatic prostate cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。